Management of patients with Long QT syndrome consists of life-style modification, beta-blockers, left cardiac sympathetic denervation, and implantable cardioverter-defibrillator implantation.
This review emphasizes a stepwise approach to LQTS management, highlighting the primary role of beta-blockers, the underutilization of LCSD, and the need for prudent patient selection for ICDs to minimize complications.
Long QT syndrome (LQTS) is a rare cardiac channelopathy associated with syncope and sudden death due to torsades de pointes and ventricular fibrillation. Syncope and sudden death are frequently associated with physical and emotional stress. Management of patients with LQTS consists of life-style modification, β-blockers, left cardiac sympathetic denervation (LCSD), and implantable cardioverter-defibrillator (ICD) implantation. Prohibition of competitive exercise and avoidance of QT-prolonging drugs are important issues in life-style modification. Although β-blockers are the primary treatment modality for patients with LQTS, these drugs are not completely effective in some patients. Lifelong ICD implantation in young and active patients is associated with significant complications. LCSD is a relatively simple and highly effective surgical procedure. However, LCSD is rarely used.
Yongkeun Cho (Fri,) conducted a review in Long QT Syndrome. Management modalities (life-style modification, beta-blockers, LCSD, ICD) was evaluated. Management of patients with Long QT syndrome consists of life-style modification, beta-blockers, left cardiac sympathetic denervation, and implantable cardioverter-defibrillator implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: